XML 30 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
Note 5. Stockholders' Equity
Dividends
On January 16, 2025, our board of directors declared a quarterly dividend of $0.43 per share of common stock to be paid in cash on February 28, 2025 to shareholders of record at the close of business on January 31, 2025. In 2024, we paid aggregate annual cash dividends per share of $1.56. We paid aggregate annual cash dividends per share of $1.78 and $1.24 in 2023 and 2022, respectively. In 2023, this included a special dividend of $0.38 per share paid in the fourth quarter.
Stock Options
Effective January 2, 2025, the compensation committee of our board of directors granted to our employees options to purchase a total of 639,304 shares of our common stock at an exercise price of $72.00 per share. On the same date, certain of our non-employee directors received options to acquire a total of 44,014 shares of our common stock at an exercise price of $72.00 per share. The closing stock price on the effective date of the grants was $71.11 per share.
The following tables summarize the details of options granted under our stock option plans that were still outstanding as of December 31, 2024, and the assumptions used to value those grants. All such grants were effective at the close of business on the date of grant.
Options
Granted		Option Exercise
Price		Closing Stock
Price on Date
of Grant		December 31, 2024
Date of GrantOptions
Outstanding		Options
Exercisable
January 2, 2024814,912 $64.00 $63.550 766,463 47,567 
January 3, 20231,071,943 $48.00 $47.400 883,852 180,820 
January 3, 2022713,438 $62.00 $61.980 529,511 197,013 
January 4, 2021741,510 $48.00 $47.650 477,333 223,592 
January 2, 2020902,263 $38.00 $37.230 514,889 313,822 
January 2, 20191,316,924 $26.00 $25.705 532,075 404,203 
January 2, 20181,087,936 $27.50 $27.270 318,598 248,436 
January 3, 20171,529,578 $23.50 $23.475 158,168 117,840 
April 19, 20161,690,880 $23.00 $22.870 47,038 47,038 
Total9,869,384 4,227,927 1,780,331 
Date of GrantRisk-free
Interest Rate		Expected Life
of Option in
Years		Expected
Dividend
Yield		Expected
Stock
Volatility		Estimated Fair
Value of Stock
Option
January 2, 20243.8% 5.002.2% 28.44 %$15.87 
January 3, 20234.0% 5.002.6% 29.58 %$11.62 
January 3, 20221.3% 5.001.7% 28.52 %$13.68 
January 4, 20210.4% 5.002.0% 29.17 %$9.57 
January 2, 20201.7% 5.002.4% 25.70 %$6.81 
January 2, 20192.5% 5.002.9% 23.96 %$4.40 
January 2, 20182.2% 5.002.3% 23.45 %$5.02 
January 3, 20171.9% 5.002.6% 24.49 %$4.20 
April 19, 20161.3% 5.002.6% 26.34 %$4.09 
All of the options in the tables above vest and become exercisable over a period of up to eight years. Generally, each option will terminate approximately 10 years after the grant date.
The fair value of each share-based option is estimated on the date of grant using a Black-Scholes valuation method that uses the assumptions listed above. The risk-free interest rate is based on the U.S. Treasury rate over the expected life of the option at the time of grant. The expected life is the average length of time over which we expect the employee groups will exercise their options, net of forfeitures, which is based on historical experience with similar grants. The dividend yield is estimated over the expected life of the option based on our current dividend payout, historical dividends paid, and expected future cash dividends. Expected stock volatilities are based on the movement of our stock price over the most recent historical period equivalent to the expected life of the option.
A summary of activities under our stock option plans consisted of the following:
Options
Outstanding
Exercise
Price (1)
Remaining
Life (2)
Outstanding as of January 1, 20244,974,078 $38.70 5.99
Granted814,912 $64.00 9.00
Exercised(1,338,085)$29.72 
Cancelled/forfeited(222,978)$48.12 
Outstanding as of December 31, 20244,227,927 $45.93 6.28
Exercisable as of December 31, 20241,780,331 $38.08 4.94
 
Options
Outstanding
Exercise
Price (1)
Remaining
Life (2)
Outstanding as of January 1, 20235,374,736 $34.37 5.66
Granted1,071,943 $48.00 9.00
Exercised(1,170,693)$25.69 
Cancelled/forfeited(301,908)$45.00 
Outstanding as of December 31, 20234,974,078 $38.70 5.99
Exercisable as of December 31, 20232,197,022 $30.88 4.54
(1) Weighted average exercise price.
(2) Weighted average remaining contractual life in years.
The total intrinsic value of stock options exercised during the years ended December 31, 2024, 2023, and 2022 was $57.6, $38.1, and $10.2, respectively. The intrinsic value represents the difference between the exercise price and fair value of the underlying shares at the date of exercise.
At December 31, 2024, there was $19.0 of total unrecognized stock-based compensation expense related to outstanding unvested stock options granted under the employee stock option plan. This expense is expected to be recognized over a weighted average period of 4.09 years. Any future change in estimated forfeitures will impact this amount. The total grant date fair value of stock options vested under our employee stock option plan during 2024, 2023, and 2022 was $7.6, $5.3, and $5.2, respectively.
Total stock-based compensation expense related to our employee stock option plan was $8.0, $7.3, and $7.2 for 2024, 2023, and 2022, respectively.
Shares Outstanding
Shares of common stock outstanding were as follows:
202420232022
Balance at beginning of year571,982,367 570,811,674 575,464,682 
Stock options exercised1,338,085 1,170,693 346,992 
Purchases of common stock— — (5,000,000)
Balance at end of year573,320,452 571,982,367 570,811,674 
Net Income Per Share
The following tables present a reconciliation of the denominators used in the computation of basic and diluted net income per share and a summary of the options to purchase shares of common stock which were excluded from the diluted net income per share calculation because they were anti-dilutive:
Reconciliation202420232022
Basic weighted average shares outstanding572,708,065 571,271,846 573,777,790 
Weighted shares assumed upon exercise of stock options1,574,146 1,736,762 1,845,324 
Diluted weighted average shares outstanding574,282,211 573,008,608 575,623,114 
Summary of Anti-dilutive Options Excluded202420232022
Options to purchase shares of common stock913,296 1,568,460 1,335,898 
Weighted average exercise prices of options$63.57 53.80 55.25 
Any dilutive impact summarized above related to periods when the average market price of our stock exceeded the exercise price of the potentially dilutive stock options then outstanding.